5.20
胆碱能拮抗剂：药代动力学
胆碱能拮抗剂（如抗毒蕈碱药），可以口服、外用、眼用、全身给药和吸入制剂。大多数抗毒蕈碱药是口服制剂，而东莨菪碱可用作局部贴片，异丙托溴铵和噻托溴铵可用作吸入气雾剂或粉末。阿托品、托吡卡胺和环喷托酯用于眼睛的滴眼液。大多数抗胆碱剂是脂溶性的，很容易从胃肠道和结膜吸收。然而，当吸入时，季铵类抗毒蕈碱药的…
胆碱能拮抗剂——例如抗毒蕈碱药——可通过口服、滴眼液、透皮贴剂、气雾剂或注射等方式给药。
需注意，季铵类抗毒蕈碱药物具有离子性质，导致其脂溶性低，难以穿透血脑屏障（BBB）。此外，它们在胃肠道、皮肤或眼部的吸收也较差。
相比之下，三级衍生物具有更高的脂溶性，能够很好地在中枢和外周被吸收。
由于这些药物的作用持续时间不同，因此被分为短效抗胆碱能药物（SAMA）和长效抗胆碱能药物（LAMA）。
它们在肝脏中通过水解或结合反应进行代谢，并经尿液排出。
抗胆碱能药物（如抗组胺药、抗精神病药或抗抑郁药）与抗毒蕈碱药物合用时，其作用会显著增强。 由于其叠加的副作用。
最后，已知抗毒蕈碱药物可部分抑制胃的蠕动运动，延缓胃排空，导致合并给药的药物吸收缓慢。
View the full transcript and gain access to JoVE Core videos
Q1: What are the different routes of administration for cholinergic antagonists?
Cholinergic antagonists are administered through multiple routes including oral formulations, topical eye drops, transdermal patches, inhalational aerosols or powders, and injections. Most antimuscarinics are available as oral formulations, while scopolamine is delivered as a topical patch. Ipratropium and tiotropium are available as inhalation aerosols or powders, and atropine, tropicamide, and cyclopentolate are topically instilled in the eye.
Q2: How does the chemical structure of antimuscarinics affect their absorption and distribution?
Quaternary antimuscarinics are ionic with low lipid solubility, resulting in poor absorption from the gut, skin, or eye and restricted penetration to the blood-brain barrier. Tertiary derivatives have higher lipid solubility and are well-absorbed both centrally and peripherally. When inhaled, quaternary antimuscarinics have limited systemic absorption due to their reduced lipid solubility.
Q3: How are antimuscarinics metabolized and eliminated from the body?
Antimuscarinics undergo hepatic metabolism through hydrolysis or conjugation and are primarily excreted via urine. Atropine rapidly metabolizes in the liver and is excreted unchanged in the urine. Most swallowed ipratropium and tiotropium are excreted through feces, while elimination of quaternary compounds is generally slower than tertiary agents.
Q4: What is the difference between short-acting and long-acting antimuscarinics?
Antimuscarinics are classified based on their duration of action as short-acting or long-acting agents. Short-acting antimuscarinics include ipratropium, while long-acting agents include glycopyrrolate, tiotropium, and aclidinium. This classification helps determine dosing frequency and clinical application for different therapeutic conditions and patient needs.
Q5: Which drugs interact with antimuscarinics and why is this clinically significant?
Antimuscarinics interact with tricyclic antidepressants, antihistamines, antianxiety agents, and antipsychotics, exacerbating antimuscarinic side effects due to additive anticholinergic properties. Additionally, antacids can increase stomach pH and form complexes with antimuscarinics, reducing their absorption. These interactions require careful monitoring during co-administration.
Q6: How do antimuscarinics affect gastric motility and drug absorption?
Antimuscarinics partially suppress peristaltic movement of the stomach, delaying gastric emptying and slowing the absorption of co-administered drugs. This effect can significantly impact the bioavailability and onset of action of other medications taken concurrently with antimuscarinics, requiring dose timing adjustments.
Q7: Why do quaternary antimuscarinics have limited systemic absorption when inhaled?
Quaternary antimuscarinics are ionic compounds with low lipid solubility, which restricts their ability to cross biological membranes. When inhaled, this reduced lipid solubility results in limited systemic absorption, allowing these agents to act primarily at local respiratory sites with minimal systemic effects and reduced side effects.